Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of atezolizumab + carboplatin + paclitaxel as first-line therapy for metastatic PD-L1-positive triple-negative breast cancer
2019-001388-55Phase 2Active
- Sponsor
- Consorzio Oncotech
- Start
- May 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, carboplatin and paclitaxel in triple-negative breast cancer (TNBC) and Metaplastic breast cancer (MpBC), sponsored by Consorzio Oncotech. Primary endpoint: Overall survival at 2 years. Started May 2021; status: active.
02
Drugs
atezolizumabcarboplatinpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)Metaplastic breast cancer (MpBC)
Beyond the preview
Go deeper on 2019-001388-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001388-55.